(Q35864072)

10 August 2017

Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease (English)

1 reference

differentiated thyroid carcinoma

10 August 2017

1 reference

Naifa Lamki Busaidy

1

1 reference

10 August 2017

Maria E Cabanillas

series ordinal

2

1 reference

10 August 2017

language of work or name

1 reference

28 February 2012

1 reference

Journal of Thyroid Research

10 August 2017

1 reference

10 August 2017

2012

1 reference

10 August 2017

618985

1 reference

Creative Commons Attribution 3.0 Unported

10 August 2017

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

11 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Phase II trial of sorafenib in metastatic thyroid cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Dedifferentiated thyroid cancer: a therapeutic challenge

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Motesanib diphosphate in progressive differentiated thyroid cancer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Phase II trial of sorafenib in advanced thyroid cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Modified radical neck dissection for differentiated thyroid cancer: operative technique

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Locally advanced thyroid cancer: therapeutic options.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

PET in the follow-up of differentiated thyroid cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

The development of breast carcinoma in women with thyroid carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

The RET proto-oncogene in human cancers

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Evaluation and treatment of aerodigestive tract invasion by well-differentiated thyroid carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Mechanisms of angiogenesis and arteriogenesis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Management of the patient with progressive radioiodine non-responsive disease

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Prognosis and treatment of brain metastases in thyroid carcinoma.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

The surgical management of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Leukaemias and cancers following iodine-131 administration for thyroid cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Papillary and follicular thyroid cancer: impact of treatment in 1578 patients

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Thyroid cancer: a lethal endocrine neoplasm

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

11 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

A phase II study of gefitinib in patients with advanced thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316972

The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma

24 September 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F618985

Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma

21 January 2018

1 reference

12 December 2020

Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas

1 reference

12 December 2020

Invasive differentiated thyroid carcinoma: tracheal resection and reconstruction procedures in the hands of the endocrine surgeon

1 reference

12 December 2020

Distant Metastases in Differentiated Thyroid Carcinoma: A Multivariate Analysis of Prognostic Variables*

1 reference

12 December 2020

Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma

1 reference

12 December 2020

Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma

1 reference

12 December 2020

Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma

1 reference

12 December 2020

Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer

1 reference

12 December 2020

Presence of BRAF V600E in very early stages of papillary thyroid carcinoma

1 reference

12 December 2020

1 reference

12 December 2020

Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients

1 reference

12 December 2020

Lung metastases from differentiated thyroid carcinoma. A 40 years' experience

1 reference

12 December 2020

Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer

1 reference

12 December 2020

Gamma knife radiosurgery for metastatic brain tumors from thyroid cancer

1 reference

12 December 2020

Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients

1 reference

12 December 2020

Chemotherapy of thyroid carcinoma

1 reference

12 December 2020

Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma

1 reference

12 December 2020

Incidence of breast carcinoma in women with thyroid carcinoma

1 reference

12 December 2020

Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer

1 reference

12 December 2020

Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas

1 reference

12 December 2020

Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma

1 reference

12 December 2020

Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy

1 reference

12 December 2020

Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma

1 reference

12 December 2020

Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan

1 reference

12 December 2020

18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer

1 reference

12 December 2020

Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer

1 reference

12 December 2020

Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma

1 reference

12 December 2020

Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan

1 reference

12 December 2020

[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels

1 reference

12 December 2020

Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer

1 reference

12 December 2020

Identifiers

DOI

10.1155/2012/618985

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

22530159

1 reference